TASER(R) Technology is Safe and Effective Based on Law Enforcement and Medical Science Experts
SCOTTSDALE, Arizona, November 30 /PRNewswire/ --
- Amnesty International Report is Out of Step With Law Enforcement Worldwide
TASER(R) International, Inc. (Nasdaq: TASR), a market leader in advanced non-lethal devices, stands behind the safety of its TASER technology and is dismayed that Amnesty International's TASER report issued today refuses to accept independent and comprehensive reports concerning the safety and effectiveness of the TASER system.
"Amnesty International's report fails to adequately describe the overwhelming body of evidence supported by independent scientific and medical experts (see compilation below) that have studied current TASER technology and its use," said Rick Smith, CEO of TASER International, Inc. "Amnesty has repeatedly called for independent testing while ignoring the mounting independent comprehensive reports showing TASER technology is safe and effective. Anyone living in the real world in which law enforcement officers worldwide have to make split-second life or death decisions knows that Amnesty International's report and position is out of step with the needs of law enforcement concerning our proven life-saving technology," said Mr. Smith.
"Independent reviews of TASER technology were recently completed by the United States Department of Defense Human Effects Center of Excellence, the United Kingdom's Defence Scientific Advisory Council, an Independent TASER Medical Task Force in Orange County, Florida, and by a host of governments from Australia to Canada," continued Mr. Smith. "These reports clearly indicate that the TASER technology, while not risk-free, is among the safest use-of-force options our law enforcement officers have."
A compendium of medical evidence is on our web site for review at: www.TASER.com/SavingLives.
"This compilation, based on independent police, medical and scientific studies clearly supports that TASER non-lethal systems are reducing injuries and saving lives every day," said Mr. Smith. "We are disappointed that Amnesty International refuses to accept the conclusions of independent medical reviewers and police experts. For years, Amnesty International has called for the ban or suspension of virtually every police tool, from pepper spray, batons, handcuffs to TASER devices. Unsuccessful in their calls to ban police technology, Amnesty International has repeatedly called for independent studies into the effects of these devices and a so-called 'suspension' of their use until such studies are completed."
"Furthermore, we are particularly disappointed by Amnesty International's complete disregard for the health and safety of the men and women of law enforcement who put their lives on the line every day to protect our society. Last year in the United States alone, over 57,000 police officers were assaulted with almost 14,000 suffering personal injuries. That is in addition to the 150 officers that were killed in the line of duty.
Amnesty International's report implies unarmed assailants do not represent a potential threat to the personal safety of law enforcement officers. Yet, over 81% of the time, police officers are assaulted with "personal weapons" -- the hands, fists, or feet of the assailants. Amnesty International's assertion that officers should place themselves in jeopardy of injury by resorting to more dangerous hand-to-hand combat techniques rather than using non-lethal, low injury TASER devices to subdue physically resistant subjects is irresponsible, dangerous, and would clearly yield more officer and subject injuries if implemented," continued Mr. Smith.
"Amnesty International should support a life-saving technology used by law enforcement to reduce suspect and officer injuries and one that has saved thousands of suspect lives," said Mr. Smith. "TASER technology is significantly and incontestably providing law enforcement an invaluable life-saving tool and is helping protect the human rights of suspects and officers alike. We have always supported and continue to support testing that reaffirms the safety of TASER technology. We also reiterate our willingness to work together with Amnesty International. We invite all persons who read the Amnesty International report to download our compilation entitled, 'TASERs: Saving Lives and Reducing Injuries,' at www.TASER.com/SavingLives and form their own conclusions," concluded Mr. Smith.
About TASER International, Inc.
TASER International, Inc. provides advanced non-lethal devices for use in the law enforcement, military, private security and personal defense markets. TASER devices use proprietary technology to safely incapacitate dangerous, combative or high-risk subjects who pose a risk to law enforcement officers, innocent citizens or themselves. TASER technology saves lives every day, and the use of TASER devices dramatically reduces injury rates for police officers and suspects. TASER technology is currently in testing or deployment at over 6,000 law enforcement and correctional agencies in the U.S. and abroad. For more information on TASER life-saving technology, please call TASER International at +1-480-444-4000 or visit our website at www.TASER.com.
Note to Investors
This press release contains forward-looking information within the meaning of Section 27A of the Securities Act of the 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the safe harbor created by those sections. The forward-looking information is based upon current information and expectations regarding TASER International. These estimates and statements speak only as of the date on which they are made, are not guarantees of future performance, and involve certain risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results could materially differ from what is expressed, implied, or forecasted in such forward-looking statements.
TASER International assumes no obligation to update the information contained in this press release. TASER International's future results may be impacted by risks associated with rapid technological change, new product introductions, new technological developments and implementations, execution issues associated with new technology, ramping manufacturing production to meet demand, litigation including lawsuits resulting from alleged product related injuries, media publicity concerning allegations of deaths occurring after use of the TASER device and the negative impact this could have on sales, product quality, implementation of manufacturing automation, potential fluctuations in quarterly operating results, competition, financial and budgetary constraints of prospects and customers, international order delays, dependence upon sole and limited source suppliers, negative reports concerning TASER device uses, fluctuations in component pricing, government regulations, variation among law enforcement agencies with their TASER product experience, dependence upon key employees, and its ability to retain employees. TASER International's future results may also be impacted by other risk factors listed from time to time in its SEC filings, including, but not limited to, the Company's Form 10-QSBs and its Annual Report on Form 10-KSB.
For further information contact Steve Tuttle, Director of Communications, at Press@TASER.com. Visit the company's web-site at www.TASER.com for facts and video.
Web site: http://www.TASER.com/SavingLives Web site: http://www.taser.com
SOURCE TASER International, Inc.
More by this Source
Greater Manchester Police To Deploy 3,000 Body Cameras on Axon Technology Platform From TASER
04 Dec, 2015, 07:00 GMT
TASER Wins Major Bid to Outfit 22,000 London Metropolitan Police Officers with Axon Body Cameras
24 Nov, 2015, 14:00 GMT
Get content for your website
Enhance your website's or blog's content with PR Newswire's customised real-time news feeds.
Contact PR Newswire
Send us an email at MarketingUK@prnewswire.co.uk or call us at +44 (0)20 7454 5382
Become a PR Newswire client
Request more information about PR Newswire products & services or call us at +44 (0)20 7454 5382